Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-DFO-pertuzumab PET/CT in HER2-Positive Malignancies
NCT03109977Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium Zr-89 DFO-pertuzumab in HER2-positive breast cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 1 year. Started Mar 2017; status: completed.
02
Drugs
zirconium Zr-89 DFO-pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03109977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109977.